

EMORY UNIVERSITY HOSPITAL MIDTOWN PRESENTS: IORT SYMPOSIUM: TARGETED INTRAOPERATIVE RADIOTHERAPY A ONE-STOP SOLUTION FOR BREAST CONSERVATION & G.I. CANCERS

Date: Friday, October 6, 2017 Time: 8:30 am – 1:30 pm Location: Emory University Hospital Midtown Glenn Auditorium 550 Peachtree Street, NE Atlanta, Georgia 30308

Agenda:

8:30am – 11:30am Didactic Session led by
Dr. Stephen Grobmyer & Dr. William Small
11:30am – 12:15pm Lunch (provided)
12:15pm – 1:30pm Simulation Lab



Speaker: Stephen R. Grobmyer, MD, FACS Professor of Surgery, Cleveland Clinic Lerner College of Medicine, and Director, Cleveland Clinic Breast Center

Dr. Grobmyer is widely known for his expertise and leadership in the development of IORT for breast cancer in the United States. In 2009, Dr. Grobmyer developed the first IORT program for breast cancer in the Southeastern United States at University of Florida. Since 2012, he has lead development and expansion of the Cleveland Clinic IORT Program, which is one of the leading IORT sites in North America.

Dr. Grobmyer serves on the Board of Directors of the US TARGIT registry and TARGIT Collaborative Group. He is the Course Director for the North American TARGIT Academy at Cleveland Clinic. He served as senior investigator for the TARGIT-R which is the largest reported experience with IORT in North America.

Speaker: William Small, Jr., MD, FACRO, FACR, FASTRO

Professor and Chairman, Department of Radiation Oncology, Stritch School of Medicine Loyola University Chicago, Cardinal Bernardine Cancer Center, Maywood, IL

Dr. Small has an international reputation for research and treatment of breast cancers, gynecological malignancies, and gastrointestinal cancers. He has long been a proponent of IORT and has spoken on the use of IORT at national professional society meetings as well as at international IORT User Meetings. He most recently was the lead author on "Commentary on the manuscript 'Accelerated Partial Breast Irradiation Consensus Statement: Update of an ASTRO Evidence-Based Consensus Statement'" for Practical Radiation Oncology. He is a National Co-Chair of the TARGIT US Registry clinical trial, and a member of the TARGIT Collaborative Group Board of Directors.

